Speciality: Oncology
Description:
A warm welcome to all the medical professionals joining us for this insightful session on the multifaceted advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies. The landscape of advanced breast cancer treatment has been profoundly reshaped by the advent of CDK4/6 inhibitors. These targeted therapies, including palbociclib, ribociclib, and abemaciclib, have revolutionized the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, demonstrating significant improvements in progression-free and overall survival rates compared to traditional endocrine therapy alone. Their mechanism of action, by selectively inhibiting cyclin-dependent kinases 4 and 6, effectively halts cell cycle progression and offers a more precise approach to combating cancer.
Dr. Bhavna Parikh, a distinguished expert in the field, will delve into the compelling clinical evidence supporting the widespread adoption of these agents. Through landmark clinical trials, CDK4/6 inhibitors have consistently shown superior efficacy, extending the time patients live without disease progression and enhancing their quality of life. This session will explore the nuances of these studies, highlighting the patient populations who benefit most, the optimal sequencing strategies, and the management of potential side effects, ensuring a comprehensive understanding of their practical application in clinical settings.
The integration of CDK4/6 inhibitors into the treatment paradigm for HR+/HER2- advanced breast cancer represents a monumental leap forward in personalized oncology. This webinar is an invaluable opportunity to gain an overall knowledge of the best practices and latest advancements in leveraging these inhibitors for improved patient outcomes. Don't miss this chance to grab the shared knowledge and follow Hidoc for more such interesting webinar sessions that keep you at the forefront of medical innovation.
See More Webinars @ Hidoc Webinars
1.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
4.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
5.
Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.
1.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
2.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
3.
Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs
4.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
5.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation